Cargando…
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
INTRODUCTION: This pooled analysis of nine phase I and II trastuzumab deruxtecan (T-DXd) monotherapy studies described drug-related interstitial lung disease (ILD)/pneumonitis in patients treated with T-DXd. METHODS: Patients who received T-DXd across nine studies were included. Investigator-assesse...
Autores principales: | Powell, C.A., Modi, S., Iwata, H., Takahashi, S., Smit, E.F., Siena, S., Chang, D.-Y., Macpherson, E., Qin, A., Singh, J., Taitt, C., Shire, N., Camidge, D. Ross |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434416/ https://www.ncbi.nlm.nih.gov/pubmed/35963179 http://dx.doi.org/10.1016/j.esmoop.2022.100554 |
Ejemplares similares
-
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review
por: Abuhelwa, Ziad, et al.
Publicado: (2022) -
Trastuzumab-Induced Interstitial Pneumonitis
por: Errisuriz, Kimberly, et al.
Publicado: (2023) -
Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2‐targeting Ab–drug conjugate, in monkeys
por: Kumagai, Kazuyoshi, et al.
Publicado: (2020) -
Trastuzumab deruxtecan for breast cancer
Publicado: (2022) -
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer
por: Hackshaw, Michelle D., et al.
Publicado: (2020)